Cargando…
Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice
OBJECTIVE: The aim of this study was to identify factors that influence treatment adjustments and adoption of a treat-to-target (T2T) strategy in patients with rheumatoid arthritis (RA) in European practices. METHODS: Cross-sectional data were drawn from the Adelphi 2014 RA Disease Specific Programm...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179241/ https://www.ncbi.nlm.nih.gov/pubmed/30323570 http://dx.doi.org/10.2147/PPA.S170054 |
_version_ | 1783362070030319616 |
---|---|
author | Taylor, Peter C Alten, Rieke Reino, Juan J Gomez Caporali, Roberto Bertin, Philippe Sullivan, Emma Wood, Robert Piercy, James Vasilescu, Radu Spurden, Dean Alvir, Jose Tarallo, Miriam |
author_facet | Taylor, Peter C Alten, Rieke Reino, Juan J Gomez Caporali, Roberto Bertin, Philippe Sullivan, Emma Wood, Robert Piercy, James Vasilescu, Radu Spurden, Dean Alvir, Jose Tarallo, Miriam |
author_sort | Taylor, Peter C |
collection | PubMed |
description | OBJECTIVE: The aim of this study was to identify factors that influence treatment adjustments and adoption of a treat-to-target (T2T) strategy in patients with rheumatoid arthritis (RA) in European practices. METHODS: Cross-sectional data were drawn from the Adelphi 2014 RA Disease Specific Programme. Treatment patterns and clinical characteristics were investigated in patients treated with biologic disease-modifying antirheumatic drugs (bDMARDs) vs non-bDMARDs. For the T2T analysis, patients were subdivided into two subsets (RA diagnosis <2 or ≥2 years) and compared according to the approach used (no target = no T2T approach; pragmatic = target different from remission; and aspirational = target set as remission). RESULTS: Data from 2,536 patients were analyzed (mean age: 52.76 years and mean time since RA diagnosis: 6.05 years). Of the 1,438 patients eligible to receive bDMARDs, 55% did not receive them. Initiation of bDMARDs in a bDMARD-naïve patient was prompted by worsening of the disease. In the RA diagnosis <2 years subset, a T2T approach was not adopted in 58% of the patients, whereas 8% and 34% adopted a pragmatic and aspirational approach, respectively. In the RA diagnosis ≥2 years subset, 45%, 19%, and 36% of the patients adopted a no target, pragmatic, and aspirational approach, respectively. Physician satisfaction with RA control was lower in the RA diagnosis <2 years subset than in the RA diagnosis ≥2 years subset (65% vs 77% satisfied, respectively; P<0.0001). CONCLUSION: This analysis shows that the use of bDMARDs remains suboptimal and that a T2T strategy is not universally adopted. |
format | Online Article Text |
id | pubmed-6179241 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61792412018-10-15 Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice Taylor, Peter C Alten, Rieke Reino, Juan J Gomez Caporali, Roberto Bertin, Philippe Sullivan, Emma Wood, Robert Piercy, James Vasilescu, Radu Spurden, Dean Alvir, Jose Tarallo, Miriam Patient Prefer Adherence Original Research OBJECTIVE: The aim of this study was to identify factors that influence treatment adjustments and adoption of a treat-to-target (T2T) strategy in patients with rheumatoid arthritis (RA) in European practices. METHODS: Cross-sectional data were drawn from the Adelphi 2014 RA Disease Specific Programme. Treatment patterns and clinical characteristics were investigated in patients treated with biologic disease-modifying antirheumatic drugs (bDMARDs) vs non-bDMARDs. For the T2T analysis, patients were subdivided into two subsets (RA diagnosis <2 or ≥2 years) and compared according to the approach used (no target = no T2T approach; pragmatic = target different from remission; and aspirational = target set as remission). RESULTS: Data from 2,536 patients were analyzed (mean age: 52.76 years and mean time since RA diagnosis: 6.05 years). Of the 1,438 patients eligible to receive bDMARDs, 55% did not receive them. Initiation of bDMARDs in a bDMARD-naïve patient was prompted by worsening of the disease. In the RA diagnosis <2 years subset, a T2T approach was not adopted in 58% of the patients, whereas 8% and 34% adopted a pragmatic and aspirational approach, respectively. In the RA diagnosis ≥2 years subset, 45%, 19%, and 36% of the patients adopted a no target, pragmatic, and aspirational approach, respectively. Physician satisfaction with RA control was lower in the RA diagnosis <2 years subset than in the RA diagnosis ≥2 years subset (65% vs 77% satisfied, respectively; P<0.0001). CONCLUSION: This analysis shows that the use of bDMARDs remains suboptimal and that a T2T strategy is not universally adopted. Dove Medical Press 2018-10-04 /pmc/articles/PMC6179241/ /pubmed/30323570 http://dx.doi.org/10.2147/PPA.S170054 Text en © 2018 Taylor et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Taylor, Peter C Alten, Rieke Reino, Juan J Gomez Caporali, Roberto Bertin, Philippe Sullivan, Emma Wood, Robert Piercy, James Vasilescu, Radu Spurden, Dean Alvir, Jose Tarallo, Miriam Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice |
title | Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice |
title_full | Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice |
title_fullStr | Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice |
title_full_unstemmed | Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice |
title_short | Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice |
title_sort | factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current european rheumatology practice |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179241/ https://www.ncbi.nlm.nih.gov/pubmed/30323570 http://dx.doi.org/10.2147/PPA.S170054 |
work_keys_str_mv | AT taylorpeterc factorsinfluencingtheuseofbiologictherapyandadoptionoftreattotargetrecommendationsincurrenteuropeanrheumatologypractice AT altenrieke factorsinfluencingtheuseofbiologictherapyandadoptionoftreattotargetrecommendationsincurrenteuropeanrheumatologypractice AT reinojuanjgomez factorsinfluencingtheuseofbiologictherapyandadoptionoftreattotargetrecommendationsincurrenteuropeanrheumatologypractice AT caporaliroberto factorsinfluencingtheuseofbiologictherapyandadoptionoftreattotargetrecommendationsincurrenteuropeanrheumatologypractice AT bertinphilippe factorsinfluencingtheuseofbiologictherapyandadoptionoftreattotargetrecommendationsincurrenteuropeanrheumatologypractice AT sullivanemma factorsinfluencingtheuseofbiologictherapyandadoptionoftreattotargetrecommendationsincurrenteuropeanrheumatologypractice AT woodrobert factorsinfluencingtheuseofbiologictherapyandadoptionoftreattotargetrecommendationsincurrenteuropeanrheumatologypractice AT piercyjames factorsinfluencingtheuseofbiologictherapyandadoptionoftreattotargetrecommendationsincurrenteuropeanrheumatologypractice AT vasilescuradu factorsinfluencingtheuseofbiologictherapyandadoptionoftreattotargetrecommendationsincurrenteuropeanrheumatologypractice AT spurdendean factorsinfluencingtheuseofbiologictherapyandadoptionoftreattotargetrecommendationsincurrenteuropeanrheumatologypractice AT alvirjose factorsinfluencingtheuseofbiologictherapyandadoptionoftreattotargetrecommendationsincurrenteuropeanrheumatologypractice AT tarallomiriam factorsinfluencingtheuseofbiologictherapyandadoptionoftreattotargetrecommendationsincurrenteuropeanrheumatologypractice |